BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruley des Varannes S, Gharib H, Bicheler V, Bost R, Bonaz B, Stanescu L, Delchier JC, Bonnot-Marlier S. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. Aliment Pharmacol Ther. 2004;20:899-907. [PMID: 15479362 DOI: 10.1111/j.1365-2036.2004.02176.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Varannes SBD, Sacher-Huvelin S, Vavasseur F, Masliah C, Rhun ML, Aygalenq P, Bonnot-Marlier S, Lequeux Y, Galmiche JP. Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: Results of a study in a primary care setting. World J Gastroenterol 2006; 12(16): 2569-2573 [PMID: 16688803 DOI: 10.3748/wjg.v12.i16.2569] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
2 Orr WC. Therapeutic options in the treatment of nighttime gastroesophageal reflux. Digestion 2005;72:229-38. [PMID: 16319458 DOI: 10.1159/000089957] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
3 Robinson M, Barone J. Review article: comparative pharmacodynamic review of rabeprazole - focus on day 1 data. Aliment Pharmacol Ther Symp Series 2006;2:315-26. [DOI: 10.1111/j.1746-6342.2006.00062.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Pallotta S, Pace F, Marelli S. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. Expert Review of Gastroenterology & Hepatology 2014;2:509-22. [DOI: 10.1586/17474124.2.4.509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
5 Ohmure H, Kanematsu-hashimoto K, Nagayama K, Taguchi H, Ido A, Tominaga K, Arakawa T, Miyawaki S. Evaluation of a Proton Pump Inhibitor for Sleep Bruxism: A Randomized Clinical Trial. J Dent Res 2016;95:1479-86. [DOI: 10.1177/0022034516662245] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
6 de Boer W, de Wit N, Geldof H, Hazelhoff B, Bergmans P, Smout A, Tytgat G. Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole? Scand J Gastroenterol 2006;41:1147-54. [PMID: 16990199 DOI: 10.1080/00365520600741546] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
7 García-Torres I, de la Mora-de la Mora I, Marcial-Quino J, Gómez-Manzo S, Vanoye-Carlo A, Navarrete-Vázquez G, Colín-Lozano B, Gutiérrez-Castrellón P, Sierra-Palacios E, López-Velázquez G, Enríquez-Flores S. Proton pump inhibitors drastically modify triosephosphate isomerase from Giardia lamblia at functional and structural levels, providing molecular leads in the design of new antigiardiasic drugs. Biochim Biophys Acta 2016;1860:97-107. [PMID: 26518348 DOI: 10.1016/j.bbagen.2015.10.021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
8 Belhocine K, Vavasseur F, Volteau C, Flet L, Touchefeu Y, Bruley des Varannes S. Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole. BMC Gastroenterol. 2014;14:128. [PMID: 25027286 DOI: 10.1186/1471-230X-14-128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Sayyadi S, Raoufi M, Arhami Dolatabadi A, Rostami M, Memary E. Ultrasonographic Assessment of Metoclopramide Administration Effectiveness in Accelerating Gastric Emptying Before Urgent Surgery in Patients with Insufficient NPO Time. Anesth Pain Med 2020;10:e107331. [PMID: 34150570 DOI: 10.5812/aapm.107331] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Hartmann G, Koehler P, Wieser H. Rapid degradation of gliadin peptides toxic for coeliac disease patients by proteases from germinating cereals. Journal of Cereal Science 2006;44:368-71. [DOI: 10.1016/j.jcs.2006.10.002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
11 Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmöller J. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65:19-31. [PMID: 18925391 DOI: 10.1007/s00228-008-0576-5] [Cited by in Crossref: 125] [Cited by in F6Publishing: 107] [Article Influence: 9.6] [Reference Citation Analysis]
12 Bruley des Varannes S. The proton-pump inhibitor test: pros and cons. Eur J Gastroenterol Hepatol. 2004;16:847-852. [PMID: 15316406 DOI: 10.1097/00042737-200409000-00005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
13 Fändriks L, Lönroth H, Pettersson A, Vakil N. Can famotidine and omeprazole be combined on a once-daily basis? Scand J Gastroenterol. 2007;42:689-694. [PMID: 17505990 DOI: 10.1080/00365520601026665] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
14 Warrington S, Baisley K, Dunn K, Boyce M, Morocutti A. Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects. Eur J Clin Pharmacol 2006;62:685-91. [PMID: 16850327 DOI: 10.1007/s00228-006-0148-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
15 Maiti R, Jaida J, Israel PL, Koyagura N, Mukkisa S, Palani A. Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety. J Pharmacol Pharmacother 2011;2:150-7. [PMID: 21897706 DOI: 10.4103/0976-500X.83278] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Bour B, Staub JL, Chousterman M, Labayle D, Nalet B, Nouel O, Pariente A, Tocque E, Bonnot-Marlier S. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther. 2005;21:805-812. [PMID: 15801915 DOI: 10.1111/j.1365-2036.2005.02413.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
17 Norris V, Baisley K, Dunn K, Warrington S, Morocutti A. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers: COMBINED ANALYSIS OF RABEPRAZOLE VS. ESOMEPRAZOLE ON INTRAGASTRIC pH. Alimentary Pharmacology & Therapeutics 2007;25:501-10. [DOI: 10.1111/j.1365-2036.2006.03221.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
18 Kodama K, Fujisaki H, Kubota A, Kato H, Hirota K, Kuramochi H, Murota M, Tabata Y, Ueda M, Harada H, Kawahara T, Shinoda M, Watanabe N, Iida D, Terauchi H, Yasui S, Miyazawa S, Nagakawa J. E3710, a New Proton Pump Inhibitor, with a Long-Lasting Inhibitory Effect on Gastric Acid Secretion. J Pharmacol Exp Ther 2010;334:395-401. [DOI: 10.1124/jpet.110.167783] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
19 Hunfeld NG, Touw DJ, Mathot RA, van Schaik RH, Kuipers EJ. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther. 2012;35:810-818. [PMID: 22324425 DOI: 10.1111/j.1365-2036.2012.05014.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]